 Molecular Targeted Therapy
"Molecular Targeted Therapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Treatments with drugs which interact with or block synthesis of specific cellular components characteristic of the individual's disease in order to stop or interrupt the specific biochemical dysfunction involved in progression of the disease.
| Descriptor ID |
D058990
|
| MeSH Number(s) |
E02.319.574
|
| Concept/Terms |
Molecular Targeted Therapy- Molecular Targeted Therapy
- Molecular Targeted Therapies
- Targeted Therapies, Molecular
- Targeted Therapy, Molecular
- Therapies, Molecular Targeted
- Therapy, Molecular Targeted
- Targeted Molecular Therapy
- Molecular Therapies, Targeted
- Molecular Therapy, Targeted
- Targeted Molecular Therapies
- Therapies, Targeted Molecular
- Therapy, Targeted Molecular
|
Below are MeSH descriptors whose meaning is more general than "Molecular Targeted Therapy".
Below are MeSH descriptors whose meaning is more specific than "Molecular Targeted Therapy".
This graph shows the total number of publications written about "Molecular Targeted Therapy" by people in UAMS Profiles by year, and whether "Molecular Targeted Therapy" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2025 | 2 | 1 | 3 | | 2024 | 0 | 1 | 1 | | 2022 | 0 | 1 | 1 | | 2021 | 1 | 2 | 3 | | 2020 | 1 | 3 | 4 | | 2019 | 1 | 8 | 9 | | 2018 | 5 | 2 | 7 | | 2017 | 2 | 5 | 7 | | 2016 | 2 | 1 | 3 | | 2015 | 1 | 5 | 6 | | 2014 | 3 | 1 | 4 | | 2013 | 2 | 2 | 4 | | 2012 | 1 | 2 | 3 | | 2011 | 3 | 4 | 7 | | 2010 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Molecular Targeted Therapy" by people in Profiles over the past ten years.
-
Neill NE, Mauro LA, Pennisi A. Novel Estrogen Receptor - Targeted Therapies in Hormone-Receptor Positive Breast Cancer. Curr Treat Options Oncol. 2025 Apr; 26(4):302-312.
-
Nadora D, Ezzati S, Bol B, Aboud O. Serendipity in Neuro-Oncology: The Evolution of Chemotherapeutic Agents. Int J Mol Sci. 2025 Mar 25; 26(7).
-
Dreher N, D?rrler AL, Kraus S, Rasche L, Higuchi T, Samnick S, Lapa C, Einsele H, Serfling SE, Buck AK, Werner RA. Myeloablative Radioligand Therapy Targeting C-X-C Motif Chemokine Receptor 4 in Advanced Multiple Myeloma. Clin Nucl Med. 2025 06 01; 50(6):495-500.
-
Elemian S, Al Hadidi S. Targeting GPRC5D in multiple myeloma. Expert Rev Anticancer Ther. 2024 May; 24(5):229-238.
-
Shirbhate E, Veerasamy R, Boddu SHS, Tiwari AK, Rajak H. Histone deacetylase inhibitor-based oncolytic virotherapy: A promising strategy for cancer treatment. Drug Discov Today. 2022 06; 27(6):1689-1697.
-
Wu CE, Chang CF, Huang CY, Yang CT, Kuo CS, Hsu PC, Chang JW. Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study. BMC Cancer. 2021 Jul 27; 21(1):859.
-
Von Suskil M, Sultana KN, Elbezanti WO, Al-Odat OS, Chitren R, Tiwari AK, Challagundla KB, Srivastava SK, Jonnalagadda SC, Budak-Alpdogan T, Pandey MK. Bruton's Tyrosine Kinase Targeting in Multiple Myeloma. Int J Mol Sci. 2021 May 27; 22(11).
-
Choi J, Manzano A, Dong W, Bellone S, Bonazzoli E, Zammataro L, Yao X, Deshpande A, Zaidi S, Guglielmi A, Gnutti B, Nagarkatti N, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Jeong K, Zhao S, Buza N, Hui P, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Odicino F, Pecorelli S, Ardighieri L, Bilguvar K, Quick CM, Silasi DA, Huang GS, Andikyan V, Clark M, Ratner E, Azodi M, Imielinski M, Schwartz PE, Alexandrov LB, Lifton RP, Schlessinger J, Santin AD. Integrated mutational landscape analysis of uterine leiomyosarcomas. Proc Natl Acad Sci U S A. 2021 04 13; 118(15).
-
Brown S, Pawlyn C, Tillotson AL, Sherratt D, Flanagan L, Low E, Morgan GJ, Williams C, Kaiser M, Davies FE, Jenner MW. Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four Trial. Clin Lymphoma Myeloma Leuk. 2021 03; 21(3):154-161.e3.
-
Paul B, Atrash S, Bhutani M, Voorhees P, Hamadeh I, Usmani SZ. An evaluation of subcutaneous daratumumab for the treatment of multiple myeloma. Expert Rev Hematol. 2020 08; 13(8):795-802.
-
Tewari KS, Sill MW, Monk BJ, Penson RT, Moore DH, Lankes HA, Ramondetta LM, Landrum LM, Randall LM, Oaknin A, Leitao MM, Eisenhauer EL, DiSilvestro P, Van Le L, Pearl ML, Burke JJ, Salani R, Richardson DL, Michael HE, Kindelberger DW, Birrer MJ. Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062). Mol Cancer Ther. 2020 11; 19(11):2363-2370.
-
He Y, Khan S, Huo Z, Lv D, Zhang X, Liu X, Yuan Y, Hromas R, Xu M, Zheng G, Zhou D. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies. J Hematol Oncol. 2020 07 27; 13(1):103.
-
Madsen SR, Hendricks AJ, Shi VY. Growing Patient Education in Dermatology: An Upside-Down Tree Analogy for Immunomodulatory Therapies J Drugs Dermatol. 2020 Jan 01; 19(1):28-29.
-
Parashar D, Geethadevi A, Aure MR, Mishra J, George J, Chen C, Mishra MK, Tahiri A, Zhao W, Nair B, Lu Y, Mangala LS, Rodriguez-Aguayo C, Lopez-Berestein G, Camara AKS, Liang M, Rader JS, Ramchandran R, You M, Sood AK, Kristensen VN, Mills GB, Pradeep S, Chaluvally-Raghavan P. miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer. Cell Rep. 2019 12 24; 29(13):4389-4406.e10.
-
Pesek RD, Gupta SK. Future therapies for eosinophilic gastrointestinal disorders. Ann Allergy Asthma Immunol. 2020 03; 124(3):219-226.
-
Yeh ETH, Ewer MS, Moslehi J, Dlugosz-Danecka M, Banchs J, Chang HM, Minotti G. Mechanisms and clinical course of cardiovascular toxicity of cancer treatment I. Oncology. Semin Oncol. 2019 12; 46(6):397-402.
-
Wang R, Song S, Harada K, Ghazanfari Amlashi F, Badgwell B, Pizzi MP, Xu Y, Zhao W, Dong X, Jin J, Wang Y, Scott A, Ma L, Huo L, Vicente D, Blum Murphy M, Shanbhag N, Tatlonghari G, Thomas I, Rogers J, Kobayashi M, Vykoukal J, Estrella JS, Roy-Chowdhuri S, Han G, Zhang S, Mao X, Song X, Zhang J, Gu J, Johnson RL, Calin GA, Peng G, Lee JS, Hanash SM, Futreal A, Wang Z, Wang L, Ajani JA. Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut. 2020 01; 69(1):18-31.
-
Paul B, Lipe B, Ocio EM, Usmani SZ. Induction Therapy for Newly Diagnosed Multiple Myeloma. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:e176-e186.
-
Zhang L, Yao Y, Zhang S, Liu Y, Guo H, Ahmed M, Bell T, Zhang H, Han G, Lorence E, Badillo M, Zhou S, Sun Y, Di Francesco ME, Feng N, Haun R, Lan R, Mackintosh SG, Mao X, Song X, Zhang J, Pham LV, Lorenzi PL, Marszalek J, Heffernan T, Draetta G, Jones P, Futreal A, Nomie K, Wang L, Wang M. Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Sci Transl Med. 2019 05 08; 11(491).
-
Barone R, Rizzo R, Tabb? G, Malaguarnera M, Frye RE, Bastin J. Nuclear Peroxisome Proliferator-Activated Receptors (PPARs) as Therapeutic Targets of Resveratrol for Autism Spectrum Disorder. Int J Mol Sci. 2019 Apr 16; 20(8).
-
Cafri G, Yossef R, Pasetto A, Deniger DC, Lu YC, Parkhurst M, Gartner JJ, Jia L, Ray S, Ngo LT, Jafferji M, Sachs A, Prickett T, Robbins PF, Rosenberg SA. Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients. Nat Commun. 2019 01 25; 10(1):449.
-
Birrer MJ, Betella I, Martin LP, Moore KN. Is Targeting the Folate Receptor in Ovarian Cancer Coming of Age? Oncologist. 2019 04; 24(4):425-429.
-
El Chaer F, Ali OM, Sausville EA, Law JY, Lee ST, Duong VH, Baer MR, Koka R, Singh ZN, Wong J, Yared JA, Griffiths EA, Emadi A. Treatment of CD19-positive mixed phenotype acute leukemia with blinatumomab. Am J Hematol. 2019 01; 94(1):E7-E8.
-
Harada K, Lopez A, Shanbhag N, Badgwell B, Baba H, Ajani J. Recent advances in the management of gastric adenocarcinoma patients. F1000Res. 2018; 7.
-
Patil A, Manzano M, Gottwein E. CK1a and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma. Blood. 2018 08 09; 132(6):577-586.
-
Pesek RD, Gupta SK. Emerging drugs for eosinophilic esophagitis. Expert Opin Emerg Drugs. 2018 06; 23(2):173-183.
-
Guimbellot J, Solomon GM, Baines A, Heltshe SL, VanDalfsen J, Joseloff E, Sagel SD, Rowe SM. Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations. J Cyst Fibros. 2019 01; 18(1):102-109.
-
Drilon A, Somwar R, Mangatt BP, Edgren H, Desmeules P, Ruusulehto A, Smith RS, Delasos L, Vojnic M, Plodkowski AJ, Sabari J, Ng K, Montecalvo J, Chang J, Tai H, Lockwood WW, Martinez V, Riely GJ, Rudin CM, Kris MG, Arcila ME, Matheny C, Benayed R, Rekhtman N, Ladanyi M, Ganji G. Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers. Cancer Discov. 2018 06; 8(6):686-695.
-
Dings RPM, Miller MC, Griffin RJ, Mayo KH. Galectins as Molecular Targets for Therapeutic Intervention. Int J Mol Sci. 2018 Mar 19; 19(3).
-
Miousse IR, Ewing LE, Kutanzi KR, Griffin RJ, Koturbash I. DNA Methylation in Radiation-Induced Carcinogenesis: Experimental Evidence and Clinical Perspectives. Crit Rev Oncog. 2018; 23(1-2):1-11.
-
Ayoub KF, Pothineni NVK, Rutland J, Ding Z, Mehta JL. Immunity, Inflammation, and Oxidative Stress in Heart Failure: Emerging Molecular Targets. Cardiovasc Drugs Ther. 2017 Dec; 31(5-6):593-608.
-
Nickoloff JA, Jones D, Lee SH, Williamson EA, Hromas R. Drugging the Cancers Addicted to DNA Repair. J Natl Cancer Inst. 2017 11 01; 109(11).
-
Zafar MK, Eoff RL. Translesion DNA Synthesis in Cancer: Molecular Mechanisms and Therapeutic Opportunities. Chem Res Toxicol. 2017 11 20; 30(11):1942-1955.
-
Guimbellot J, Sharma J, Rowe SM. Toward inclusive therapy with CFTR modulators: Progress and challenges. Pediatr Pulmonol. 2017 Nov; 52(S48):S4-S14.
-
Martin LP, Konner JA, Moore KN, Seward SM, Matulonis UA, Perez RP, Su Y, Berkenblit A, Ruiz-Soto R, Birrer MJ. Characterization of folate receptor alpha (FRa) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRa-targeting antibody-drug conjugate mirvetuximab soravtansine. Gynecol Oncol. 2017 11; 147(2):402-407.
-
Zawistowski JS, Bevill SM, Goulet DR, Stuhlmiller TJ, Beltran AS, Olivares-Quintero JF, Singh D, Sciaky N, Parker JS, Rashid NU, Chen X, Duncan JS, Whittle MC, Angus SP, Velarde SH, Golitz BT, He X, Santos C, Darr DB, Gallagher K, Graves LM, Perou CM, Carey LA, Earp HS, Johnson GL. Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex. Cancer Discov. 2017 03; 7(3):302-321.
-
Kieber-Emmons T, Makhoul I, Pennisi A, Siegel ER, Emanuel PD, Monzavi-Karbassi B, Steplewski Z, Beck JT, Hutchins LF. Managing Expectations in the Transition to Proof of Concept Studies. Rev Recent Clin Trials. 2017; 12(2):111-123.
-
Upreti M, Jyoti A, Johnson SE, Swindell EP, Napier D, Sethi P, Chan R, Feddock JM, Weiss HL, O'Halloran TV, Evers BM. Radiation-enhanced therapeutic targeting of galectin-1 enriched malignant stroma in triple negative breast cancer. Oncotarget. 2016 Jul 05; 7(27):41559-41574.
-
Sarkar S, Raymick J, Imam S. Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives. Int J Mol Sci. 2016 Jun 08; 17(6).
-
Bishop MW, Janeway KA, Gorlick R. Future directions in the treatment of osteosarcoma. Curr Opin Pediatr. 2016 Feb; 28(1):26-33.
-
Fouda AY, Artham S, El-Remessy AB, Fagan SC. Renin-angiotensin system as a potential therapeutic target in stroke and retinopathy: experimental and clinical evidence. Clin Sci (Lond). 2016 Feb; 130(4):221-38.
-
Moran-Jones K, Gloss BS, Murali R, Chang DK, Colvin EK, Jones MD, Yuen S, Howell VM, Brown LM, Wong CW, Spong SM, Scarlett CJ, Hacker NF, Ghosh S, Mok SC, Birrer MJ, Samimi G. Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer. Oncotarget. 2015 Dec 29; 6(42):44551-62.
-
Schlumberger M, Jarzab B, Cabanillas ME, Robinson B, Pacini F, Ball DW, McCaffrey J, Newbold K, Allison R, Martins RG, Licitra LF, Shah MH, Bodenner D, Elisei R, Burmeister L, Funahashi Y, Ren M, O'Brien JP, Sherman SI. A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer. Clin Cancer Res. 2016 Jan 01; 22(1):44-53.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|